{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:14Z","timestamp":1781636054914,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Recently miR-15a-5p, miR-20a-5p and miR-33b-3p were found to be abnormally expressed in multiple myeloma (MM) patients. However, the significance of these microRNAs in MM pathogenesis remains poorly understood. Therefore the aim of the current study was to make an integrated bioinformatics analysis of miR-15a-5p, miR-20a-5p and miR-33b-3p to identify the biological processes in MM pathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>Steven K. Thompson<\/jats:italic>\n                      equation and a-priori power analysis was conducted to determine the minimum sample size required. Forty patients with newly diagnosed MM and staged by the International Staging System (ISS) and 20 healthy bone marrow donors were included in our study. The baseline bone marrow miR-15a-5p, miR-20a-5p and miR-33b-3p expression levels were evaluated by RTqPCR technique. Moreover, EGR2 expression level was evaluated by using immunohistochemistry. A bioinformatics analysis for miR-15a-5p, miR-20a-5p, miR-33b-3p and EGR2 was done by using miRNet and miRDB (for target genes prediction), GO analysis and KEGG analysis (for biological processes identification) and STRING database (for PPI network).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The target genes of miR-15a-5p, miR-20a-5p and miR-33b-3p were retrieved then GO analysis was done which showed that the pathway with many shared target genes was MAPK signaling pathway that involved in the cell cycle control. The baseline bone marrow miR-15a-5p, miR-20a-5p&amp; miR-33b-3p expression levels were significantly decreased (0.29\u2009\u00b1\u20090.04,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001;0.42\u2009\u00b1\u20090.06,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001;0.51\u2009\u00b1\u20090.07,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02 fold-change relative to controls) in MM patients when compared to controls (1.04\u2009\u00b1\u20090.11,1.02\u2009\u00b1\u20090.07&amp;1.05\u2009\u00b1\u20090.11;respectively) while EGR2 protein was significantly increased in MM patients when compared to controls. Results obtained from ROC curve revealed that miR-15a-5p\u2009+\u2009miR-20a-5p\u2009+\u2009miR-33b-3p panel (AUC\u2009=\u20090.98, 100%sensitivity, 85%specificity,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and EGR2 protein expression (AUC\u2009=\u20090.986, 97.5%sensitivity, 90%specificity,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) were the best ones as diagnostic biomarkers could differentiate MM disease. By using Kaplan\u2009\u2212\u2009Meier survival test, the mean (95%CI) for OS was 24.08 (21.58\u201329.88) months throughout the 32-month follow-up period for MM patients, our results indicated that patients with lower expression levels of miR-15a-5p, miR-20a-5p&amp;miR-33b-3p and higher expression level of EGR2 protein had poorer prognosis and possessing a shorter OS. The logistic regression analysis indicates that miR-15a-5p, miR-20a-5p, and miR-33b-3p are risk factors for the development of MM (OR\u2009=\u20099.36,2.56,4.76; 95% CI 4.02\u201321.28,1.28\u20135.32,2.43\u20139.16;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001;respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Finally miR-15a-5p, miR-20a-5p, and miR-33b-3p may have roles in MM pathogenesis through cell cycle control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15610-5","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:54:09Z","timestamp":1770890049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated analysis of miR-15a-5p, miR-20a-5p, and miR-33b-3p identifies EGR2-associated biomarkers in multiple myeloma"],"prefix":"10.1186","volume":"26","author":[{"given":"Riham Abdel-Hamid","family":"Haroun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada M.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar S.","family":"Elshazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma F. Abdel","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Nabil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"15610_CR1","doi-asserted-by":"publisher","first-page":"1413494","DOI":"10.3389\/fonc.2024.1413494","volume":"14","author":"K Lu","year":"2024","unstructured":"Lu K, Wang W, Liu Y, Xie C, Liu J, Xing L. Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment. Front Oncol. 2024;14:1413494. https:\/\/doi.org\/10.3389\/fonc.2024.1413494.\u00a0","journal-title":"Front Oncol"},{"key":"15610_CR2","doi-asserted-by":"publisher","unstructured":"Elsaid DS, Elbedewy TAE, Hamza MA, Haroun RA. The role of interleukin-20 and vascular endothelial growth factor-A biomarkers in the detection of renal impairment in patients with multiple myeloma. Expert Rev Hematol. 2024. https:\/\/doi.org\/10.1080\/17474086.2024.2417085.\u00a0","DOI":"10.1080\/17474086.2024.2417085"},{"issue":"27\u201328","key":"15610_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3238\/arztebl.2016.0470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016;113(27\u201328):470\u20136. https:\/\/doi.org\/10.3238\/arztebl.2016.0470.\u00a0","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"15610_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1158\/0008-5472.CAN-23-1950","volume":"84","author":"JP Sasine","year":"2024","unstructured":"Sasine JP, Kozlova NY, Valicente L, Dukov J, Tran DH, Himburg HA, et al. Inhibition of Ephrin B2 reverse signaling abolishes multiple myeloma pathogenesis. Cancer Res. 2024;84(6):919\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1950.","journal-title":"Cancer Res"},{"issue":"2","key":"15610_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/s-0042-1748184","volume":"12","author":"N Sood","year":"2022","unstructured":"Sood N, Tiwari AK, Pabbi S, Dikshit R, Singh P, Ramaswami A, et al. Clinical outcomes of autologous hematopoietic stem cell transplant in multiple myeloma patients: A 5-year experience from a single centre in North India. South Asian J Cancer. 2022;12(2):185\u20139. https:\/\/doi.org\/10.1055\/s-0042-1748184.\u00a0","journal-title":"South Asian J Cancer"},{"issue":"11","key":"15610_CR6","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/cancers11111738","volume":"11","author":"H Handa","year":"2019","unstructured":"Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y. The role and function of MicroRNA in the pathogenesis of multiple myeloma. Cancers (Basel). 2019;11(11):1738. https:\/\/doi.org\/10.3390\/cancers11111738.\u00a0","journal-title":"Cancers (Basel)"},{"issue":"9","key":"15610_CR7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3390\/jpm12091428","volume":"12","author":"A Szudy-Szczyrek","year":"2022","unstructured":"Szudy-Szczyrek A, Ahern S, Krawczyk J, Szczyrek M, Hus M. MiRNA as a potential target for multiple myeloma Therapy-Current knowledge and perspectives. J Pers Med. 2022;12(9):1428. https:\/\/doi.org\/10.3390\/jpm12091428.\u00a0","journal-title":"J Pers Med"},{"issue":"21","key":"15610_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3978\/j.issn.2305-5839.2015.12.13","volume":"3","author":"M Rossi","year":"2015","unstructured":"Rossi M, Tagliaferri P, Tassone P. MicroRNAs in multiple myeloma and related bone disease. Ann Transl Med. 2015;3(21):334. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.12.13.\u00a0","journal-title":"Ann Transl Med"},{"issue":"1","key":"15610_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s43141-023-00565-y","volume":"21","author":"RA Haroun","year":"2023","unstructured":"Haroun RA, Osman WH, Eessa AM. Prognostic significance of serum miR-18a-5p in severe COVID-19 Egyptian patients. J Genet Eng Biotechnol. 2023;21(1):114. https:\/\/doi.org\/10.1186\/s43141-023-00565-y.\u00a0","journal-title":"J Genet Eng Biotechnol"},{"issue":"1","key":"15610_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pathol.2021.09.006","volume":"54","author":"RA Haroun","year":"2022","unstructured":"Haroun RA, Osman WH, Amin RE, Hassan AK, Abo-Shanab WS, Eessa AM. Circulating plasma miR-155 is a potential biomarker for the detection of SARS-CoV-2 infection. Pathology. 2022;54(1):104\u201310. https:\/\/doi.org\/10.1016\/j.pathol.2021.09.006.\u00a0","journal-title":"Pathology"},{"issue":"7","key":"15610_CR11","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/genes14071375","volume":"14","author":"A Chakrabortty","year":"2023","unstructured":"Chakrabortty A, Patton DJ, Smith BF, Agarwal P. MiRNAs: potential as biomarkers and therapeutic targets for cancer. Genes (Basel). 2023;14(7):1375. https:\/\/doi.org\/10.3390\/genes14071375.\u00a0","journal-title":"Genes (Basel)"},{"issue":"11","key":"15610_CR12","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1182\/blood.V106.11.1554.1554","volume":"106","author":"A Al Masri","year":"2005","unstructured":"Al Masri A, Price-Troska T, Chesi M, Chung TH, Kim S, Carpten J, et al. MicroRNA expression analysis in multiple myeloma. Blood. 2005;106(11):1554.","journal-title":"Blood"},{"issue":"1","key":"15610_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.BCD-19-0068","volume":"1","author":"M Chesi","year":"2020","unstructured":"Chesi M, Stein CK, Garbitt VM, Sharik ME, Asmann YW, Bergsagel M, et al. Monosomic loss of MIR15A\/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov. 2020;1(1):68\u201381. https:\/\/doi.org\/10.1158\/0008-5472.BCD-19-0068.\u00a0","journal-title":"Blood Cancer Discov"},{"key":"15610_CR14","doi-asserted-by":"publisher","first-page":"RP87900","DOI":"10.1101\/2023.04.14.536843","volume":"12","author":"BD Wheeler","year":"2023","unstructured":"Wheeler BD, Gagnon JD, Zhu WS, Mu\u00f1oz-Sandoval P, Wong SK, Simeonov DR, et al. The LncRNA Malat1 inhibits miR-15\/16 to enhance cytotoxic T cell activation and memory cell Formation. BioRxiv [Preprint]. 2023 Jul 29:2023.04.14.536843. Update In: Elife. 2023;12:RP87900. https:\/\/doi.org\/10.1101\/2023.04.14.536843.\u00a0","journal-title":"Update In: Elife"},{"key":"15610_CR15","doi-asserted-by":"publisher","unstructured":"Tavakoli Pirzaman A, Ebrahimi P, Hasanpour AH, Shakeri M, Babajani B, Pourali Ganji Z, et al. MiRNAs and multiple myeloma: focus on the Pathogenesis, Prognosis, and drug resistance. Technol Cancer Res Treat. 2023;22:15330338231202391. https:\/\/doi.org\/10.1177\/15330338231202391.\u00a0","DOI":"10.1177\/15330338231202391"},{"issue":"1","key":"15610_CR16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1186\/s12885-018-4907-3","volume":"18","author":"D Huang","year":"2018","unstructured":"Huang D, Peng Y, Ma K, Deng X, Tang L, Jing D, et al. MiR-20a, a novel promising biomarker to predict prognosis in human cancer: a meta-analysis. BMC Cancer. 2018;18(1):1189. https:\/\/doi.org\/10.1186\/s12885-018-4907-3.\u00a0","journal-title":"BMC Cancer"},{"issue":"1","key":"15610_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3892\/ol.2017.7299","volume":"15","author":"L Wei","year":"2018","unstructured":"Wei L, Ran F. MicroRNA-20a promotes proliferation and invasion by directly targeting early growth response 2 in non-small cell lung carcinoma. Oncol Lett. 2018;15(1):271\u20137. https:\/\/doi.org\/10.3892\/ol.2017.7299.\u00a0","journal-title":"Oncol Lett"},{"key":"15610_CR18","doi-asserted-by":"publisher","first-page":"740452","DOI":"10.3389\/fonc.2021.740452","volume":"11","author":"Y Mei","year":"2021","unstructured":"Mei Y, Li K, Zhang Z, Li M, Yang H, Wang H, et al. miR-33b-3p acts as a tumor suppressor by targeting DOCK4 in prostate cancer. Front Oncol. 2021;11:740452. https:\/\/doi.org\/10.3389\/fonc.2021.740452\u00a0.","journal-title":"Front Oncol"},{"issue":"2","key":"15610_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/or.2023.8476","volume":"49","author":"W Yu","year":"2023","unstructured":"Yu W, Ma L, Li X. DANCR promotes glioma cell autophagy and proliferation via the MiR 33b\/DLX6\/ATG7 axis. Oncol Rep. 2023;49(2):39. https:\/\/doi.org\/10.3892\/or.2023.8476.\u00a0","journal-title":"Oncol Rep"},{"key":"15610_CR20","doi-asserted-by":"publisher","unstructured":"Thompson SK, The American Statistician. Sample size for estimating multinomial proportions. 1987;41(1): 42\u201346. (1987). https:\/\/doi.org\/10.1080\/00031305.1987.10475440.","DOI":"10.1080\/00031305.1987.10475440"},{"key":"15610_CR21","doi-asserted-by":"publisher","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5 .\u00a0","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"15610_CR22","doi-asserted-by":"publisher","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20. https:\/\/doi.org\/10.1200\/JCO.2005.04.242. Erratum in: J Clin Oncol. 2005;23(25):6281. Harousseau, Jean-Luc [corrected to Avet-Loiseau, Herve]. PMID: 15809451.","DOI":"10.1200\/JCO.2005.04.242"},{"issue":"3","key":"15610_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/leu.2009.274","volume":"24","author":"NC Guti\u00e9rrez","year":"2010","unstructured":"Guti\u00e9rrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, et al. Deregulation of MicroRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010;24(3):629\u201337. https:\/\/doi.org\/10.1038\/leu.2009.274.","journal-title":"Leukemia"},{"issue":"12","key":"15610_CR24","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41417-020-00291-4","volume":"28","author":"D Chen","year":"2021","unstructured":"Chen D, Yang X, Liu M, Zhang Z, Xing E. Roles of MiRNA dysregulation in the pathogenesis of multiple myeloma. Cancer Gene Ther. 2021;28(12):1256\u201368. https:\/\/doi.org\/10.1038\/s41417-020-00291-4.\u00a0","journal-title":"Cancer Gene Ther"},{"key":"15610_CR25","doi-asserted-by":"publisher","unstructured":"Haroun RA, Eweida SM, Elsaid DS, Al-Dosoky MA, Elbedewy TA, Keshk RA, et al. Downexpression of miR- 17\u20135p and miR- 125a- 5p is Potentially Associated with the Renal Impairment Through STAT- 3 and CD69 in Multiple Myeloma Adult Patients. Biochem Genet. 2025. https:\/\/doi.org\/10.1007\/s10528-025-11094-3.","DOI":"10.1007\/s10528-025-11094-3"},{"issue":"14","key":"15610_CR26","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1038\/s41388-022-02227-8","volume":"41","author":"PJ Teoh","year":"2022","unstructured":"Teoh PJ, An O, Chung TH, Vaiyapuri T, Raju A, Hoppe MM, et al. p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 Inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain). Oncogene. 2022;41(14):2106\u201321. https:\/\/doi.org\/10.1038\/s41388-022-02227-8.\u00a0","journal-title":"Oncogene"},{"issue":"14","key":"15610_CR27","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.3390\/ijms21145002","volume":"21","author":"S Akhtar","year":"2020","unstructured":"Akhtar S, Ali TA, Faiyaz A, Khan OS, Raza SS, Kulinski M, et al. Cytokine-Mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma. Int J Mol Sci. 2020;21(14):5002. https:\/\/doi.org\/10.3390\/ijms21145002.\u00a0","journal-title":"Int J Mol Sci"},{"key":"15610_CR28","doi-asserted-by":"publisher","first-page":"999939","DOI":"10.3389\/fonc.2022.999939","volume":"12","author":"TG Dadzie","year":"2022","unstructured":"Dadzie TG, Green AC. The role of the bone microenvironment in regulating myeloma residual disease and treatment. Front Oncol. 2022;12:999939. https:\/\/doi.org\/10.3389\/fonc.2022.999939. PMID: 36072809; PMCID: PMC9441696.","journal-title":"Front Oncol"},{"key":"15610_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.freeradbiomed.2023.04.003","volume":"203","author":"Z Yin","year":"2023","unstructured":"Yin Z, Lv Y, Deng L, Li G, Ou R, Chen L, et al. Targeting ABCB6 with nitidine chloride inhibits PI3K\/AKT signaling pathway to promote ferroptosis in multiple myeloma. Free Radic Biol Med. 2023;203:86\u2013101.\u00a0","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"15610_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s12859-022-05077-z","volume":"23","author":"M Kim","year":"2022","unstructured":"Kim M, Kim E. Mathematical model of the cell signaling pathway based on the extended boolean network model with a stochastic process. BMC Bioinformatics. 2022;23(1):515. https:\/\/doi.org\/10.1186\/s12859-022-05077-z.\u00a0","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"15610_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5(1):25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w.","journal-title":"Mol Biomed"},{"issue":"11","key":"15610_CR32","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.3390\/ijms25116065","volume":"25","author":"AI Gkioka","year":"2024","unstructured":"Gkioka AI, Tsota M, Koudouna A, Gkiokas A, Mitropoulou CA, Palaiokrassa A, et al. Circulating miR-16 and miR-21 levels in multiple myeloma: prognostic significance of survival and response to Lenalidomide treatment. Int J Mol Sci. 2024;25(11):6065. https:\/\/doi.org\/10.3390\/ijms25116065.\u00a0","journal-title":"Int J Mol Sci"},{"issue":"11","key":"15610_CR33","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569\u201375. https:\/\/doi.org\/10.1182\/blood-2002-10-3017.","journal-title":"Blood"},{"key":"15610_CR34","doi-asserted-by":"publisher","unstructured":"Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis. 2013;34(2):426\u2009\u2013\u200935. https:\/\/doi.org\/10.1093\/carcin\/bgs333.\u00a0","DOI":"10.1093\/carcin\/bgs333"},{"issue":"21","key":"15610_CR35","doi-asserted-by":"publisher","first-page":"30876","DOI":"10.18632\/oncotarget.9021","volume":"7","author":"L Zhang","year":"2016","unstructured":"Zhang L, Pan L, Xiang B, Zhu H, Wu Y, Chen M, et al. Potential role of exosome-associated MicroRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget. 2016;7(21):30876\u201391. https:\/\/doi.org\/10.18632\/oncotarget.9021.\u00a0","journal-title":"Oncotarget"},{"key":"15610_CR36","doi-asserted-by":"publisher","first-page":"114432","DOI":"10.1016\/j.biopha.2023.114432","volume":"161","author":"W Zhang","year":"2023","unstructured":"Zhang W, Jiang B, Zhu H, Cheng A, Li C, Huang H, et al. miR-33b in human cancer: mechanistic and clinical perspectives. Biomed Pharmacother. 2023;161:114432. https:\/\/doi.org\/10.1016\/j.biopha.2023.114432.\u00a0","journal-title":"Biomed Pharmacother"},{"issue":"19","key":"15610_CR37","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1182\/blood-2012-01-401794","volume":"120","author":"Z Tian","year":"2012","unstructured":"Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, et al. Investigational agent MLN9708\/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012;120(19):3958\u201367. https:\/\/doi.org\/10.1182\/blood-2012-01-401794.\u00a0","journal-title":"Blood"},{"issue":"7","key":"15610_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.leukres.2015.04.010","volume":"39","author":"F Li","year":"2015","unstructured":"Li F, Hao M, Feng X, Zang M, Qin Y, Yi S, et al. Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leuk Res. 2015;39(7):793\u20139. https:\/\/doi.org\/10.1016\/j.leukres.2015.04.010.\u00a0","journal-title":"Leuk Res"},{"issue":"6","key":"15610_CR39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41419-024-06841-0","volume":"15","author":"O Olarewaju","year":"2024","unstructured":"Olarewaju O, Hu Y, Tsay HC, Yuan Q, Eimterb\u00e4umer S, Xie Y, et al. MicroRNA miR-20a-5p targets CYCS to inhibit apoptosis in hepatocellular carcinoma. Cell Death Dis. 2024;15(6):456. https:\/\/doi.org\/10.1038\/s41419-024-06841-0.\u00a0","journal-title":"Cell Death Dis"},{"issue":"6","key":"15610_CR40","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jmoldx.2015.06.006","volume":"17","author":"W Wang","year":"2015","unstructured":"Wang W, Corrigan-Cummins M, Barber EA, Saleh LM, Zingone A, Ghafoor A, et al. Aberrant levels of MiRNAs in bone marrow microenvironment and peripheral blood of myeloma patients and disease progression. J Mol Diagn. 2015;17(6):669\u201378. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.06.006.\u00a0","journal-title":"J Mol Diagn"},{"issue":"21","key":"15610_CR41","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.3390\/cancers13215258","volume":"13","author":"SR Moura","year":"2021","unstructured":"Moura SR, Abreu H, Cunha C, Ribeiro-Machado C, Oliveira C, Barbosa MA, et al. Circulating MicroRNAs correlate with multiple myeloma and skeletal osteolytic lesions. Cancers (Basel). 2021;13(21):5258. https:\/\/doi.org\/10.3390\/cancers13215258.\u00a0","journal-title":"Cancers (Basel)"},{"issue":"12","key":"15610_CR42","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.7150\/jca.96481","volume":"15","author":"H Xiao","year":"2024","unstructured":"Xiao H, Huang X, Chen H, Zheng Y, Liu W, Chen J, et al. Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer. J Cancer. 2024;15(12):3841\u201356. https:\/\/doi.org\/10.7150\/jca.96481.\u00a0","journal-title":"J Cancer"},{"issue":"5","key":"15610_CR43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/cancers16051033","volume":"16","author":"M Dubaj","year":"2024","unstructured":"Dubaj M, Bigosi\u0144ski K, Dembowska A, Mlak R, Szudy-Szczyrek A, Ma\u0142ecka-Massalska T, et al. Role of Non-Coding RNAs in Diagnosis, prediction and prognosis of multiple myeloma. Cancers (Basel). 2024;16(5):1033. https:\/\/doi.org\/10.3390\/cancers16051033.\u00a0","journal-title":"Cancers (Basel)"},{"issue":"6","key":"15610_CR44","doi-asserted-by":"publisher","first-page":"e23233","DOI":"10.1002\/jcla.23233","volume":"34","author":"J Li","year":"2020","unstructured":"Li J, Zhang M, Wang C. Circulating MiRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. J Clin Lab Anal. 2020;34(6):e23233. https:\/\/doi.org\/10.1002\/jcla.23233.\u00a0","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"15610_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hon.2639","volume":"37","author":"ZY Zhang","year":"2019","unstructured":"Zhang ZY, Li YC, Geng CY, Zhou HX, Gao W, Chen WM. Serum Exosomal MicroRNAs as novel biomarkers for multiple myeloma. Hematol Oncol. 2019;37(4):409\u201317. https:\/\/doi.org\/10.1002\/hon.2639.\u00a0","journal-title":"Hematol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15610-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:09:30Z","timestamp":1781633370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15610-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15610"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15610-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is in agreement with the ethical guidelines of the Declaration of Helsinki and it follows the Institutional Review Board, National Cancer Institute, Cairo University, Cairo, Egypt (IRB00004025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}